Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-tissue Sarcoma
View/ Open
Author
Yoon, Sam
Stangenberg, Lars
Lee, Yoon-Jin
Rothrock, Courtney
Dreyfuss, Jonathan
Baek, Kwan-Hyuck
Waterman, Peter
Nielsen, G. Petur
Weissleder, Ralph
Mahmood, Umar
Park, Peter
Jacks, Tyler
Dodd, Rebecca
Fisher, Carolyn
Ryeom, Sandra
Kirsch, David
Published Version
https://doi.org/10.1016/j.ijrobp.2009.02.052Metadata
Show full item recordCitation
Yoon, Sam S., Lars Stangenberg, Yoon-Jin Lee, Courtney Rothrock, Jonathan M. Dreyfuss, Kwan-Hyuck Baek, Peter R. Waterman, et al. 2009. “Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma.” International Journal of Radiation Oncology*Biology*Physics 74 (4): 1207–16. https://doi.org/10.1016/j.ijrobp.2009.02.052.Abstract
Purpose: Sunitinib (SU) is a multitargeted receptor tyrosine kinase inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors. The present study examined SU and radiotherapy (RT) in a genetically engineered mouse model of soft tissue sarcoma (STS). Methods: and Materials: Primary extremity STSs were generated in genetically engineered mice. The mice were randomized to treatment with SU, RT (10 Gy x 2), or both (SU+RT). Changes in the tumor vasculature before and after treatment were assessed in vivo using fluorescence-mediated tomography. The control and treated tumors were harvested and extensively analyzed. Results: The mean fluorescence in the tumors was not decreased by RT but decreased 38-44% in tumors treated with SU or SU+RT. The control tumors grew to a mean of 1378 mm(3) after 12 days. SU alone or RT alone delayed tumor growth by 56% and 41%, respectively, but maximal growth inhibition (71%) was observed with the combination therapy. SU target effects were confirmed by loss of target receptor phosphorylation and alterations in SU-related gene expression. Cancer cell proliferation was decreased and apoptosis increased in the SU and RT groups, with a synergistic effect on apoptosis observed in the SU+RT group. RT had a minimal effect on the tumor microvessel density and endothelial cell-specific apoptosis, but SU alone or SU+RT decreased the microvessel density by >66% and induced significant endothelial cell apoptosis. Conclusion: SU inhibited STS growth by effects on both cancer cells and tumor vasculature. SU also augmented the efficacy of RT, suggesting that this combination strategy could improve local control of STS.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384316
Collections
- HMS Scholarly Articles [17918]
Contact administrator regarding this item (to report mistakes or request changes)